Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI

Launched by ASSIUT UNIVERSITY · Aug 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying new blood tests (called biomarkers) that might help doctors predict a complication called “no-reflow” in patients having a certain type of heart attack (called STEMI) treated with a procedure to open blocked arteries (primary PCI). No-reflow happens when blood flow doesn’t fully return to the heart muscle even after the artery is opened, which can affect recovery. The trial will look at three specific blood measurements to see if they can help identify patients at risk for this problem.

Adults 18 years and older who are having this emergency heart procedure and can give their permission to join may be eligible. People who have had previous heart attacks or heart procedures, serious kidney or liver problems, ongoing infections, or certain other health issues won’t be able to participate. If you take part, doctors will use your blood test results to learn if these new markers can better predict who might experience no-reflow during treatment. This study is not yet recruiting participants, but it aims to help improve care for heart attack patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Suitable for and undergoing timely primary PCI based on symptoms and clinical judgment
• • Provision of informed consent
• Exclusion Criteria:
• • History of previous MI, PCI, or CABG
• • Known chronic inflammatory or autoimmune diseases
• • Advanced renal or hepatic failure
• • Active infection or malignancy at presentation
• • Incomplete data or refusal to consent